CN102666589B - EphA3抗体 - Google Patents

EphA3抗体 Download PDF

Info

Publication number
CN102666589B
CN102666589B CN201080056618.XA CN201080056618A CN102666589B CN 102666589 B CN102666589 B CN 102666589B CN 201080056618 A CN201080056618 A CN 201080056618A CN 102666589 B CN102666589 B CN 102666589B
Authority
CN
China
Prior art keywords
seq
antibody
sequence
region
epha3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080056618.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102666589A (zh
Inventor
肯尼思·鲁尔森
大卫·马迪尼兹
克里斯蒂娜·伊
克里斯托弗·R·贝炳东
杰弗里·T·亚兰东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hermanigan
Original Assignee
Kalobios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc
Publication of CN102666589A publication Critical patent/CN102666589A/zh
Application granted granted Critical
Publication of CN102666589B publication Critical patent/CN102666589B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201080056618.XA 2009-10-14 2010-10-14 EphA3抗体 Active CN102666589B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25166809P 2009-10-14 2009-10-14
US61/251,668 2009-10-14
PCT/US2010/052725 WO2011053465A1 (en) 2009-10-14 2010-10-14 Antibodies to epha3

Publications (2)

Publication Number Publication Date
CN102666589A CN102666589A (zh) 2012-09-12
CN102666589B true CN102666589B (zh) 2014-08-20

Family

ID=43499991

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080056618.XA Active CN102666589B (zh) 2009-10-14 2010-10-14 EphA3抗体

Country Status (11)

Country Link
US (2) US8664365B2 (cg-RX-API-DMAC7.html)
EP (1) EP2488554B1 (cg-RX-API-DMAC7.html)
JP (2) JP2013508292A (cg-RX-API-DMAC7.html)
CN (1) CN102666589B (cg-RX-API-DMAC7.html)
AU (1) AU2010313621C1 (cg-RX-API-DMAC7.html)
CA (1) CA2777068C (cg-RX-API-DMAC7.html)
DK (1) DK2488554T3 (cg-RX-API-DMAC7.html)
ES (1) ES2743558T3 (cg-RX-API-DMAC7.html)
PL (1) PL2488554T3 (cg-RX-API-DMAC7.html)
PT (1) PT2488554T (cg-RX-API-DMAC7.html)
WO (1) WO2011053465A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123819A2 (en) * 2010-04-01 2011-10-06 Kalobios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of multiple myeloma
WO2011160132A2 (en) * 2010-06-18 2011-12-22 Kalobios Pharmaceuticals, Inc. Detection of epha3 as a marker of the presence of a solid tumor
AU2012295334A1 (en) 2011-08-12 2013-05-02 Kalobios Pharmaceuticals, Inc. Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP3512883A1 (en) 2016-09-13 2019-07-24 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
EP3758751A4 (en) 2018-02-28 2021-11-17 Wuxi Biologics Ireland Limited. MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF
US20260055195A1 (en) * 2019-10-09 2026-02-26 The Council Of The Queensland Institute Of Medical Research Targeting epha3 and uses thereof
EP4054602A4 (en) * 2019-11-08 2023-12-06 Mayo Foundation for Medical Education and Research EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS
US20240025971A1 (en) * 2020-10-23 2024-01-25 Atreca, Inc. Antibodies to coronavirus sars-cov-2
CN118055945A (zh) * 2021-08-06 2024-05-17 韩国生命工学研究院 新型抗epha2嵌合抗原受体和表达其的免疫细胞

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112192A2 (en) * 2007-03-08 2008-09-18 Kalobios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of solid tumors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ATE278019T1 (de) 1991-06-21 2004-10-15 Inst Medical W & E Hall Neuartige rezeptor-typ tyrosinkinase und deren verwendung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
NO175798C (no) 1992-07-22 1994-12-07 Sinvent As Fremgangsmåte og anordning til aktiv stöydemping i et lokalt område
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CA2923247A1 (en) 2002-03-19 2003-09-25 Stichting Dienst Landbouwkundig Onderzoek Optimizing glycan processing in plants
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US7981843B2 (en) 2004-01-20 2011-07-19 Kalobios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
PL2343380T3 (pl) 2004-11-16 2020-03-31 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
US8211648B2 (en) 2005-07-22 2012-07-03 Kalobios Pharmaceuticals, Inc. Secretion of antibodies without signal peptides from bacteria
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008060092A1 (en) 2006-11-17 2008-05-22 Sang Yun Park Rotative force generator
CL2008002782A1 (es) 2007-09-21 2009-07-31 Genentech Inc Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
US8834870B2 (en) 2009-03-06 2014-09-16 Kalobios Pharmaceuticals, Inc. Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112192A2 (en) * 2007-03-08 2008-09-18 Kalobios Pharmaceuticals, Inc. Epha3 antibodies for the treatment of solid tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cilloni D, Catalano R, Chiarenza A, et al. EphA3 is abnormally expressed in chronic myeloprolipherative disorders and can be targeted by dasatinib or by monoclonal antibodies;Cilloni D, Catalano R, Chiarenza A, et al;《Haematologica》;20071231;248-249 *
酪氨酸激酶受体Eph基因及其与肿瘤的关系;王建东;《医学研究生学报》;20061031;第19卷(第10期);935-938 *

Also Published As

Publication number Publication date
AU2010313621A1 (en) 2012-05-03
DK2488554T3 (da) 2019-09-02
CA2777068C (en) 2020-05-26
CN102666589A (zh) 2012-09-12
ES2743558T3 (es) 2020-02-19
US20110123549A1 (en) 2011-05-26
US9290571B2 (en) 2016-03-22
AU2010313621B2 (en) 2015-07-30
US8664365B2 (en) 2014-03-04
US20140120114A1 (en) 2014-05-01
JP2016094424A (ja) 2016-05-26
AU2010313621C1 (en) 2015-11-26
JP2013508292A (ja) 2013-03-07
EP2488554A1 (en) 2012-08-22
PL2488554T3 (pl) 2020-03-31
WO2011053465A1 (en) 2011-05-05
CA2777068A1 (en) 2011-05-05
PT2488554T (pt) 2019-09-13
EP2488554B1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
US9290571B2 (en) Antibodies to EphA3
JP2025163156A (ja) 抗ctla4抗体およびその使用方法
JP2018126150A (ja) Tl1aと結合する抗体およびその使用
KR102860769B1 (ko) 항-ccr8 항체
AU2012274104B2 (en) Anti-CXCR4 antibody with effector functions and its use for the treatment of cancer.
WO2022166846A1 (zh) 抗tnfr2抗体及其用途
US9045539B2 (en) Anti-EMR1 antibodies
KR20240004694A (ko) 항체
HK40109194A (en) Antibodies
WO2025067442A1 (zh) 抗fgfr2抗体和包含其的多特异性结合分子
HK40100657A (en) Anti-ccr8 antibodies
HK40100657B (en) Anti-ccr8 antibodies
EA053247B1 (ru) Антитела к ctla4 и способы их применения
HK40064169A (en) Anti-ctla4 antibodies and methods of use thereof
CN104254340A (zh) 通过靶向骨髓中异常血管系统上表达的EphA3来治疗血液增殖性疾病的方法
NZ618655B2 (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer.
TW201305336A (zh) 具作用功能的抗cxcr4抗體及其供治療癌症之用途
OA16794A (en) Anti-CXCR4 antibody with effector functions and its use for the treatment of cancer.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: California, USA

Patentee after: Hermanigan

Address before: California, USA

Patentee before: KALOBIOS PHARMACEUTICALS, Inc.